<html xmlns="http://www.w3.org/1999/xhtml" xmlns="http://www.w3.org/1999/xhtml">
 <head xmlns="http://www.w3.org/1999/xhtml">
 <title xmlns="http://www.w3.org/1999/xhtml"></title>
 </head>
 <body xmlns="http://www.w3.org/1999/xhtml">
 
 Coming together with thousands of leading clinicians who treat patients 
 with chronic pain, <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.neurometrix.com%2F&amp;esheet=51526365&amp;newsitemid=20170315006016&amp;lan=en-US&amp;anchor=NeuroMetrix%2C+Inc.&amp;index=1&amp;md5=2810fd364e10ddeca156668a43654b7c" rel="nofollow" rel="nofollow">NeuroMetrix, 
 Inc.</a> NURO will exhibit <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.quellrelief.com%2F&amp;esheet=51526365&amp;newsitemid=20170315006016&amp;lan=en-US&amp;anchor=Quell%C2%AE&amp;index=2&amp;md5=846778204f79f34bc8e2cdb62efed095" rel="nofollow" rel="nofollow">Quell®</a>, 
 its FDA-cleared, 100% drug-free wearable designed to provide widespread 
 relief from chronic pain, at the American Academy of Pain Medicine 
 (AAPM) <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.painmed.org%2Fannualmeeting%2F&amp;esheet=51526365&amp;newsitemid=20170315006016&amp;lan=en-US&amp;anchor=33rd+Annual+Meeting&amp;index=3&amp;md5=3d1dbb2429efae4f75439b0203052f3d" rel="nofollow" rel="nofollow">33rd 
 Annual Meeting</a> in Orlando, Fla., March 15-19, 2017 at booth #418.
 
 
 The theme of this year's AAPM annual meeting is "Pain as a Public Health 
 Issue," and will cover educational content around the pressing need for 
 pain clinicians to address this major public health burden through 
 evidence-based treatments in practice. With nearly 100 million Americans 
 living with chronic pain, and an estimated $635 billion spent a year on 
 chronic pain management, NeuroMetrix is dedicated to meaningful 
 innovation and bringing relief to those living with chronic pain with 
 the latest technology.
 
 
 "For one in three Americans, chronic pain continues to disrupt their 
 everyday life, and they are continually looking to their clinicians for 
 alternative treatments to alleviate their pain," said Shai N. Gozani, 
 M.D., Ph.D. "Quell empowers those living with chronic pain to reclaim 
 their life through advanced technology. We're looking forward to 
 connecting with leading pain clinicians at this year's meeting to bring 
 more awareness to technological alternatives that can be shared with 
 their patients."
 
 
 Quell combines advanced neurotechnology in a wearable format with a 
 sophisticated app for users to personalize and control therapy, while 
 tracking their pain and relevant health metrics. The product has made a 
 difference in tens of thousands of lives since its introduction in 2015. 
 In a clinical study published last year in the Journal of Pain Research, 
 81 percent of subjects reported improvement in their chronic pain, and 
 67 percent reported a reduction in their use of pain medication after 60 
 days of using Quell.
 
 
 The AAPM 33rd Annual Meeting will be held March 15-19, 2017 
 at the Loews Sapphire Falls Resort at Universal Orlando in Orlando, Fla. 
 Attendees can learn more about Quell by visiting the NeuroMetrix booth, 
 #418 during the conference and following along on Twitter <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.twitter.com%2Fquellrelief&amp;esheet=51526365&amp;newsitemid=20170315006016&amp;lan=en-US&amp;anchor=%40Quellrelief&amp;index=4&amp;md5=122e6df9f43cabbd85eb94bca02fdc80" rel="nofollow" rel="nofollow">@Quellrelief</a>.
 
 
 About Quell
 
 
 Quell is designed for millions of people suffering from chronic pain. 
 The advanced wearable device is lightweight and can be worn during the 
 day while active, and at night while sleeping. It has been cleared by 
 the FDA for treatment of chronic pain without a prescription. In a 
 recent study, 81% of Quell users reported an improvement in their 
 chronic pain. Quell users can personalize and manage therapy discreetly 
 via the Quell Relief app. Quell also offers advanced health tracking 
 relevant to chronic pain sufferers including pain, sleep, activity, and 
 gait. Quell was the winner of the 2016 SXSW (South by Southwest) 
 Innovation Award for Best Wearable Technology. Quell is available at 
 select healthcare professionals and retailers. Visit <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.quellrelief.com&amp;esheet=51526365&amp;newsitemid=20170315006016&amp;lan=en-US&amp;anchor=QuellRelief.com&amp;index=5&amp;md5=787d15ce344c9eb8a571ae6d3eab28ff" rel="nofollow" rel="nofollow">QuellRelief.com</a> 
 for more information.
 
 
 About NeuroMetrix
 
 
 NeuroMetrix is a commercial stage, innovation driven healthcare company 
 combining bioelectrical and digital medicine to address chronic health 
 conditions including chronic pain, sleep disorders, and diabetes. The 
 company&#39;s lead product is Quell, an over-the-counter wearable 
 therapeutic device for chronic pain. Quell is integrated into a digital 
 health platform that helps patients optimize their therapy and decrease 
 the impact of chronic pain on their quality of life. The company also 
 markets DPNCheck®, a rapid point-of-care test for diabetic 
 neuropathy, which is the most common long-term complication of Type 2 
 diabetes. The company maintains an active research effort and has 
 several pipeline programs. The company is located in Waltham, 
 Massachusetts and was founded as a spinoff from the Harvard-MIT Division 
 of Health Sciences and Technology in 1996. For more information, please 
 visit <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.NeuroMetrix.com&amp;esheet=51526365&amp;newsitemid=20170315006016&amp;lan=en-US&amp;anchor=www.NeuroMetrix.com&amp;index=6&amp;md5=79690654fd5978bd26c7afc7d82081e7" rel="nofollow" rel="nofollow">www.NeuroMetrix.com</a>.
 
 <img xmlns="http://www.w3.org/1999/xhtml" alt="" src="http://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20170315006016r1&amp;sid=benz2&amp;distro=nx&amp;lang=en"></img>View source version on businesswire.com: <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.businesswire.com/news/home/20170315006016/en/" rel="nofollow" rel="nofollow">http://www.businesswire.com/news/home/20170315006016/en/</a></body></html>

Press Releases

NeuroMetrix Brings Quell Wearable for Pain Relief to American Academy of Pain Medicine 33rd Annual Meeting - NeuroMetrix (NASDAQ:NURO)

NeuroMetrix

NURO

NUROW

NeuroMetrix Brings Quell Wearable for Pain Relief to American Academy of Pain Medicine 33rd Annual Meeting

THE CANNABIST CO HLDG by THE CANNABIST COMPANY HOLDINGS INC.

CBSTF


Collaboration Now Reaches Four States including Delaware and West Virginia


The Cannabist Company Holdings Inc. (Cboe CA: CBST) (OTCQX:CBSTF) (FSE: 3LP) (&#34;The Cannabist Company&#34; or the &#34;Company&#34;), one of the largest

The Cannabist Company and Airo Brands Continue Successful Partnership with Expansion into Pennsylvania and Virginia

ARWR


Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced its plan to host a 2024 Summer Series of R&amp;D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the

Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&amp;D Webinars


HCA Healthcare, Inc. (NYSE:HCA) today announced financial and operating results for the first quarter ended March 31, 2024.


Key first quarter metrics (all percentage changes compare 1Q 2024 to 1Q 2023 unless otherwise

HCA Healthcare Reports First Quarter 2024 Results

IONQ


Independent Director of the Board Harry You–former CFO of Accenture and Oracle–also appointed as next Lead Independent Director of the Board


IonQ (NYSE:IONQ), a leader in the quantum computing industry, announced

IonQ Unanimously Appoints Peter Chapman as Next Chairman of the Board of Directors


Are you fully prepared to complete your BEAD State Challenge Process? If not, your path to success just got easier. The Sanborn Map Company&#39;s (Sanborn) Broadband Navigator™ is now available on the NASPO

Sanborn&#39;s Broadband Navigator™ is Available for Streamlined Purchase on NASPO

INVE


Identiv, Inc. (NASDAQ:INVE), a global leader in digital security and identification in the Internet of Things (IoT), will hold a teleconference and webcast on Wednesday, May 8, 2024 at 5:00 PM EDT to discuss its